Literature DB >> 11411965

Azathiopine-steroid combination therapy for pulmonary arterial aneurysms in Behçet's disease.

T Acican1, O U Gürkan.   

Abstract

Vasculitis is the primary pathological feature of Behçet's disease and in which pulmonary arterial aneurysm formations are rare but serious complications representing poor prognosis. There is no agreement on how to treat major venous and arterial disease. The use of steroids alone or corticosteroid treatment supplemented with cyclophosphamide or azathioprine is still controversial. We present three young male patients with Behçet's disease with aneurysms in the pulmonary arteries. In two of them, cyclophosphamide was the first choice of treatment, but this was ceased due to side effects. All three patients were then treated with azathioprine (2 mg/kg per day) and methylprednisolone (1.5 mg/kg per day). All three showed clinical improvement. Regression was observed radiologically in two (one minimal and the other complete). No complication related to therapy was encountered. Steroid therapy supplemented with azathioprine may be a good choice for treatment of pulmonary arterial aneurysms in Behçet's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11411965     DOI: 10.1007/s002960100102

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  3 in total

1.  Chronicle of a death foretold: a case of catastrophic vascular Behcet's disease.

Authors:  David Planer; David Leibowitz; Yair Elitzur; Amit Korach; Nurith Hiller; Tova Chajek-Shaul
Journal:  Clin Rheumatol       Date:  2006-06-08       Impact factor: 2.980

2.  Intracardiac thrombus and pulmonary aneurysms in an adolescent with Behçet disease.

Authors:  Asaf Vivante; Yoram Bujanover; Jeffrey Jacobson; Shai Padeh; Yackov Berkun
Journal:  Rheumatol Int       Date:  2008-10-11       Impact factor: 2.631

3.  Pulmonary artery aneurysms in Behçet's disease.

Authors:  Sema Yilmaz; Kadriye Akar Cimen
Journal:  Rheumatol Int       Date:  2009-08-20       Impact factor: 2.631

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.